Cargando…

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults

Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuntao, Yang, Yunkai, Qiao, Niu, Wang, Xuewei, Ding, Ling, Zhu, Xiujuan, Liang, Yu, Han, Zibo, Liu, Feng, Zhang, Xinxin, Yang, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815383/ https://www.ncbi.nlm.nih.gov/pubmed/35122211 http://dx.doi.org/10.1007/s11684-021-0914-x

Ejemplares similares

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy
por: Dick, Aharon, et al.
Publicado: (2022)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years
por: Zhang, Yukai, et al.
Publicado: (2022)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
por: Guven, D.C.C., et al.
Publicado: (2022)

Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
por: Zhang, Yuntao, et al.
Publicado: (2022)

Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants
por: Wu, Zhiwei, et al.
Publicado: (2022)

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
por: Fitz-Patrick, David, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial
por: Nafar, Mohsen, et al.
Publicado: (2022)

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults
por: Hedrick, James, et al.
Publicado: (2019)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
por: Ai, Jingwen, et al.
Publicado: (2022)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China
por: Tang, Xuewen, et al.
Publicado: (2023)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
por: Zhang, Yuntao, et al.
Publicado: (2022)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan
por: Sonoyama, Takuhiro, et al.
Publicado: (2023)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi
por: Al Kaabi, Nawal, et al.
Publicado: (2023)

Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care
por: Bijani, Behzad, et al.
Publicado: (2019)

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vela63q44na3ur5q951i10qf49